Biologics, also known as biologic response modifiers, have produced dramatic results in many patients who use them to treat rheumatoid arthritis and related conditions. Patients have been warned to weigh the benefits and risks associated with this class of drugs, the first of which was marketed in 1998. Previous studies have suggested that the biologics, especially TNF blockers, may be associated with an increased risk of developing cancer.
- Biologic Response Modifier: What is it?
- Unsuitable Candidates for Biologic Drugs
- TNF Blockers (Enbrel, Remicade, Humira) - Test Your Knowledge
A new study, reported in the September 2006 issue of Arthritis & Rheumatism, reveals that it may not be the case that biologics increase cancer risk. Researchers from Harvard Medical School in the United States and the University of British Columbia in Vancouver reviewed the medical records of 1,152 patients who took one of the biologics (either a TNF blocker or anakinra). The researchers also analyzed medical records of 7,306 patients who took methotrexate. From their comparative research, it was concluded that patients taking one of the biologics are "unlikely to have a substantial increase" in developing cancer compared to patients taking methotrexate.
More Related Resources:
- Fast Facts About Rheumatoid Arthritis
- Rheumatoid Arthritis Screening Quiz
- Test Your Knowledge: Rheumatoid Arthritis
- Rheumatoid Arthritis 101: Free E-Course Newsletter
- 10 Things You Should Know About Rheumatoid Arthritis
Image © A.D.A.M.
Comments
No comments yet. Leave a Comment
